Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (vol 21, 391, 2020)
Open Access
- 8 June 2020
- journal article
- correction
- Published by Springer Science and Business Media LLC in Trials
- Vol. 21 (1), 1-2
- https://doi.org/10.1186/s13063-020-04408-w
Abstract
An amendment to this paper has been published and can be accessed via the original article.This publication has 1 reference indexed in Scilit: